RVNC - Revance Therapeutics Inc. (RVNC) CEO Daniel Browne on Q3 2018 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (RVNC)
Q3 2018 Earnings Conference Call
November 1, 2018, 16:30 ET
Executives
Jeanie Herbert - Senior Director of IR & Corporate Communications
Daniel Browne - Co-Founder, CEO, President & Director
Cyril Allouche - Head of Finance, Interim Principal Finance & Accounting Officer and Corporate Controller
Abhay Joshi - COO
Analysts
Timothy Lugo - William Blair & Company
Christopher Staral - Goldman Sachs Group
Michael Ingerman - Piper Jaffray Companies
Louise Chen - Cantor Fitzgerald & Co.
Serge Belanger - Needham & Company
Difei Yang - Mizuho Securities
Seamus Fernandez - Guggenheim Securities